NCT05543187View on ClinicalTrials.gov

A Study of TAK-625 for the Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC)

PHASE3CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

January 10, 2023

Primary Completion Date

September 4, 2023

Study Completion Date

July 22, 2025

Conditions
Progressive Familial Intrahepatic Cholestasis (PFIC)
Interventions
DRUG

TAK-625

TAK-625 orally, twice daily (BID)

Trial Locations (8)

Unknown

University of Tsukuba Hospital, Tsukuba

Yokohamashi Tobu Hospital, Yokohama

Tsuyama Chuo Hospital, Tsuyama

Osaka University Hospital, Suita

Juntendo University Hospital, Bunkyo-ku

Kyushu University Hospital, Fukuoka

Kyoto University Hospital, Kyoto

Saitama Prefectural Children's Medical Center, Saitama

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY

NCT05543187 - A Study of TAK-625 for the Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC) | Biotech Hunter | Biotech Hunter